Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant S-1 plus docetaxel by intraperitoneal versus intravenous administration after radical surgery for locally advanced gastric cancer
ChiCTR-IPR-15006202Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegafur and docetaxel in gastric cancer (GC) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Disease-free survival. Planned start Apr 2015; status: not yet recruiting.
02
Drugs
tegafurdocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006202.